BioSpace News Archive

Bryan Katz joins KCR’s growing executive team to take over as head of commercial strategy and global partnerships

This new study data demonstrates the performance of AmpliMARK™ in hematological malignancies, and suggests that it can provide high resolution, target-rich insights for clinicians and patients to better, and less invasively, manage these diseases.

Complete fourth quarter and full-year 2019 financial results will be announced on Wednesday, February 19, 2020.

Dr. Hans S. Keirstead, AIVITA’s Chairman and CEO, will present at the following time and location:

Growth accelerated in Q4 2019, with preliminary record total revenue of $7.4 million and record product sales of $6.6 million, driven by a 30% increase in direct sales.

Crowe hospital data analysis shows wide pricing disparities among healthcare providers

AUE, an Industry-Leading Ultrasound Service Company, Worked Closely With Tulsa Technology Center to Earn Milestone Quality Management Certificate

Emulate’s Duodenum Intestine-Chip provides a robust system for preclinical drug assessment of drug transport, metabolism, and drug-drug interactions in the intestine

Nurix will utilize its proprietary drug discovery platform, DELigase™, that integrates its DNA-encoded libraries and its unparalleled portfolio of E3 ligases to create small molecules designed to induce degradation of three specified drug targets, with an option by Sanofi to expand to a total of five targets.

Clinical Trial Underway for Next-Gen Vault-Free Stereotactic Radiosurgery Platform